NYMX Projected Dividend Yield

Ord/Nymox Pharmaceutical Corp ( NASDAQ : NYMX )

Nymox Pharmaceutical is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia and the treatment of low-grade localized prostate cancer. Co. has developed and markets NicAlert™ and TobacAlert™, which are test strips for determining whether a person is using tobacco products (NicAlert™) or has been exposed to second-hand smoke (TobacAlert™). Both NicAlert™ and TobacAlert™ employ the patented technology of Co.'s subsidiary, Serex, Inc., to provide a read-out of levels of cotinine, a by-product of the body's breakdown of nicotine and generally regarded as the indicator of tobacco exposure for smokers and nonsmokers.

20 YEAR PERFORMANCE RESULTS

NYMX Dividend History Detail
NYMX Dividend News
NYMX Competitors News
# of Shares: 0 Closing Price: 0.20 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor